Nöropatik ağrı açısından fibromyalji sendromu

Klinik kullanımda lehte sonuçları olmasına rağmen, migren tedavisinde büyük oksipital sinir bloğunun (GON) etkisine dair az sayıda kanıt bulunmaktadır. Bir ön çalışmayla migren ataklarının önlenmesinde % 0,5 Fibromyalji sendromu (FMS), sinir sistemindeki primer anormalliklerin kliniğe yansıması ile karşımıza çıkan kronik ağrı sendromlarından biridir. FMS’lu hastalar, nöropatik ağrının yaygın klinik özelliklerini göstermektedirler. Bu semptom ve bulguları açıklayacak mekanizma halen anlaşılmış değildir. Santral ağrının hiperaljezi, allodini, ağrı ilişkili beyin bölgelerinin anormal aktivasyonu, anormal temporal sumasyon gibi nöropatik ağrı sendromu konusunda güçlü kanıtlara neden olan bir takım anormallikleri, FMS’lu hastaların çoğunda gözlenmektedir. Bu yeni bilgiler, santral sinir sisteminde sensitizasyon ve sempatik hiperaktiviteyle ilişkili, FMS’unun nöropatik ağrı sendromu olabileceğini düşündürmektedir. Bu farklı bakış açısı, tedavi ve çalışmalar için yeni kapılar açılmasına neden olmaktadır. Bu derlemede, FMS’unun nasıl nöropatik ağrı sendromu ile ilişkilendirildiğine dair bilgilerin sentezi yapılacaktır.
Anahtar Kelimeler:

Nevralji, Fibromiyalji, Ağrı

Fibromyalgia syndrome from the perspective of neuropathic pain

Fibromyalgia Syndrome from the Perspective of Neuropathic Pain Fibromyalgia syndrome (FMS) is one of the several chronic pain syndromes and have been proposed to reflect some primary abnormality of the nervous system. Patients with FMS display common clinical features with neuropathic pain. The responsible mechanisms for symptoms and signs are still unknown. Mounting evidence was shown for central pain processing abnormalities in almost all FMS patients. These anomalies including hyperalgesia, allodynia, abnormal activation of pain-related brain regions and abnormal temporal summation of second pain in FMS patients strongly indicate a neuropathic pain syndrome. This new information led to the proposal that FMS may be a neuropathic pain syndrome maintained by central nervous system sensitization and sympathetic hyperactivity. This different perspective on FMS opens new avenues for research and treatment. In this review, a synthesis of the information about how FMS is related to neuropathic pain syndromes is provided.
Keywords:

Neuralgia, Fibromyalgia, Pain,

Kaynakça

Arnold LM,Goldenberg DL,Stanford SB,Lalonde JK, Sandhu HS, Keck PE Jr, Welge JA,

Bishop F, Stanford KE, Hess EV, Hudson JI. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum.2007; 56: 1336-44

Bengtsson A, Bengtsson M. Regional sympathetic blockade in primary fibromyalgia. Pain.1988; 33: 161-7.

Bennett R. Fibromyalgia: present to future. Curr Pain Headache Rep. 2004; 8: 379-84.

Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Normal hypot halamo-pituitary-adrenal axis function in a rat model of peripheral neuropathic pain. Brain Res. 2005; 1044: 216-26.

Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: modera tion by a polymorphism in the 5-HTT gene. Science.2003; 301: 386-9.

Clauw DJ. Elusive syndromes: treating the biologic basis of fibromyalgia and related syndromes. Cleve Clin J Med. 2001 Oct;68(10):830, 832-4.

Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia:what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003; 17: 685-701.

Cohen H, Neumann L, Kotler M, Buskila D. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders.Isr Med Assoc J. 2001; 3: 755-60.

Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum. 2002; 46: 845-7.

Cohen S, Abdi S. Central pain. Curr Opin Anaesthesiol 2002; 15:575-81.

Crofford LJ. The relationship of fibromyalgia to neuropathic pain syndromes. J Rheumatol 2005; 32: 41-45.

Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A,Cohen P, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum. 2003; 48: 1420-9.

Dworkin RH, Fields HL. Fibromyalgia from the perspective of neuropathic pain. J Rheumatol Suppl. 2005 Aug;75:1-5.

Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004; 292: 2388-95.

Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N.Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003; 23: 104-7.

Kooh M, Martinez-Lavin M, Meza S, Martin-del-Campo A,Hermosillo AG, Pineda C, et al. Simultaneous heart rate variability and polysomnographic analyses in fibromyalgia. Clin Exp Rheumatol. 2003;21: 529-30.

Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum. 1998; 41: 1966-71.

Martinez-Lavin M, Vidal M, Barbosa RE, Pineda C, Casanova JM,Nava A. Norepinephrine-evoked pain in fibromyalgia. A randomized pilot study [ISRCTN70707830]. BMC Musculoskelet Disord. 2002; 3:2.

Martinez-Lavin M, Lopez S, Medina M, Nava A. Use of the leeds assessment of neuropathic symptoms and signs questionnaire in patients with fibromyalgia. Semin Arthritis Rheum. 2003; 32: 407-11.

Martinez-Lavin M. Fibromyalgia as a sympathetically maintained pain syndrome. Curr Pain Headache Rep. 2004;8: 385-9.

Martinez-Lavin M. Fibromyalgia is a neuropathic pain syndrome. J Rheumatol. 2006; 33: 827-8.

Mease P. Fibromyalgia Syndrome: Review of clinical presentation,pathogenesis, outcome measures, and treatment. J Rheumatol 2005; 32: 6-21.

Merskey H, Bogduk N. Classification of chronic pain. In IASP Task Force on Toxonomy. Seattle: IASP Press; 1994.

Pamuk ON, Yesil Y, Cakir N. Factors that affect the number of tender points in fibromyalgia and chronic widespread pain patients who did not meet the ACR 1990 criteria for fibromyalgia: are tender points a reflection of neuropat hic pain? Semin Arthritis Rheum. 2006; 36: 130-4.

Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H.Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol. 2000; 27: 2660-5

Rowbotham MC. Is fibromyalgia a neuropathic pain syndrome?J Rheumatol Suppl. 2005; 75: 38-40.

Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D,Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994; 37: 1593-601.

Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003; 37: 1561-5.

Simms RW, Goldenberg DL. Symptoms mimicking neurologic disorders in fibromyalgia syndrome. J Rheumatol 1988;15: 1271-3.

Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafa xine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003; 60: 1284-9.

Staud R, Domingo M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med. 2001; 2: 208-15.

Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD.Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001; 91: 165-75.

Staud R. Fibromyalgia pain: do we know the source? Curr Opin Rheumatol. 2004; 16: 157-63.

Tasmuth T, Härtel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6:17-24

Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999; 33: 160-72.

White KP, Harth M. Classification epidemiology and natural history of fibromyalgia. Curr Pain Headache Rep 2001;5: 320-9.

Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990;33:160-72.

Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms,mechanisms, and management. Lancet. 1999; 353: 1959-64.

Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y,et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science.2003; 299: 1240-3.

Kaynak Göster